Schizophrenia Treatment Adherence Investigation (STAI)

Janssen-Cilag Pty Ltd550 enrolled

Overview

The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia.

The primary objective of this treatment review and feedback program is to quantify the risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia. Observational study - no study drug administered

Study Type

OBSERVATIONAL

Enrollment

550

Conditions

Schizophrenia Schizoaffective Disorder

Interventions

Risk status for medication adherenceOTHER

Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of schizophrenia or schizoaffective disorder according to DSM-IV * Currently treated in an outpatient clinic * Able to provide informed consent * Concurrent enrolment in clinical trials is acceptable * Have completed all questions on the Drug Attitude Inventory (DAI-10) and Medication Adherence Rating Scale (MARS) survey Exclusion Criteria: * N/A

Outcomes

Primary Outcomes

Primary outcome measure is the Clinical Assessment of Adherence as rated by the Investigators

Time frame: 6 months, 12 months

Secondary Outcomes

Clinical exacerbations (worsening of symptoms)

Time frame: 6 mths, 12 mths

Medication changes

Time frame: 6 mths, 12 mths

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.